Skip to main content
SpringerLink
Log in

Akute myeloische Leukämie

  • Chapter
Therapiekonzepte Onkologie

  • 56 Accesses

Zusammenfassung

Maligne Erkrankung hämatopoetischer Stammzellen überwiegend der myeloischen bzw. myelomonozytären Reihe mit teilweisem oder völligem Verlust der Fähigkeit zur Differenzierung bei erhaltener Proliferationskapazität.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Pedersen-Bjergaard J, Philip P, Larsen SO et al. (1993) Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen Series. Leukemia 7: 1975–1986

    PubMed  CAS  Google Scholar 

  2. Cline MJ (1994) The molecular basis of leukemia. N Engl J Med 330: 328–336

    Article  PubMed  CAS  Google Scholar 

  3. Bennett JM, Catovsky D, Daniel MT et al. (1985) Proposed revised criteria of the classification of acute myeloid leukemia. Ann Intern Med 103: 626–629

    Article  Google Scholar 

  4. Cheson BD, Cassileth PA, Head DR et al. (1990) Report of the National Cancer Institutesponsored workshop on definitions of diagnosis and response on acute myeloid leukemia. J Clin Oncol 8: 813–819

    PubMed  CAS  Google Scholar 

  5. Büchner T (1993) Akute myeloische Leukämie. Internist 34: 511–517

    PubMed  Google Scholar 

  6. Groupe Français de Cytogénétique Hématologique (GFCH) (1994) Acute leukemia treated with intensive chemotherapie in patients with a history of previous chemo-and/or radiotherapy: prognostic significance of karyotype and preceding myelodysplastic syndrome. Leukemia 8: 87–91

    Google Scholar 

  7. Büchner T, Urbanitz D, Hiddemann Wet al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589

    Google Scholar 

  8. Hayat M, Jehn U, Willemze R et al. (1986) A randomized comparison of maintenance treatment with androgens, immunotherapy and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC. Cancer 58: 617–623

    Google Scholar 

  9. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ (1986) Principal results of the Medical Research Council’s 8th acute myeloid leukemia trial. Lancet II: 1236–1241

    Google Scholar 

  10. Preisler H, Davis RB, Kirshner J et al. (1987) Comparison of three remission induction regimes and two postinducton strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B Study. Blood 69: 1441–1449

    Google Scholar 

  11. Hansen OP, Pedersen-Bjergaard J, Ellegaard J et al. (1991) Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia 5: 510–516

    PubMed  CAS  Google Scholar 

  12. Dillman RO, Davis RB, Green MR et al. (1991) A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase II trial of Cancer and Leukemia Group B. Blood 78: 2520–2526

    Google Scholar 

  13. Cassileth PA, Andersen JW, Bennet JM et al. (1992) Escalating the intensity of postremission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. Leukemia: 116–119

    Google Scholar 

  14. Zittoun R, Liso V, Mandelli F et al. (1992) Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myeloid leukemia (AML) in first remission. A EORTC/GIMEMA phase III trial (AML8 B). Leukemia 6: 7677

    Google Scholar 

  15. Vogler WR, Velez-Garcia E, Weiner RS et al. (1992) A phase III trial comparing idarubicin and daunorubicin combination with cytarabine in acute myelogenous leukemia: a South-Eastern Cancer Study Group Study. J Clin Oncol 10: 103–1111

    Google Scholar 

  16. Büchner T, Hiddemann W, Wörmann B et al. (1994) Chemotherapy intensity and long-term outcome in AML. In: Büchner T et al. (eds): Acute Leukemias IV: 513–518

    Google Scholar 

  17. Heinemann V, Jehn U (1991) Acute myeloid leukemia in the elderly: biological features and search for adequate treatment. Ann Hematol 63: 179–188

    Article  PubMed  CAS  Google Scholar 

  18. Auerbach M (1994) Acute myeloid leukemia in patients more than 50 years of age: special considerations in diagnosis, treatment and prognosis. Am J Med 96: 180–185

    Article  PubMed  CAS  Google Scholar 

  19. Huang Mel Ye YC, Chen SR (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567–572

    Google Scholar 

  20. Castaigne S, Chomienne C, Daniel MT (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood 76: 1704–1709

    PubMed  CAS  Google Scholar 

  21. Warrell RP, Frankel SR, Miller WH et al. (1991) Differentiation therapy for acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324: 1385–1393

    Article  PubMed  Google Scholar 

  22. Degos L (1994) Is acute promyelocytic leukemia a curable disease? Treatment strategy for a long-term survival. Leukemia 8: 911–913

    PubMed  CAS  Google Scholar 

  23. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Samo E, Frei E (1992) Intensive post-remission therapy with ARA-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. Leukemia 6: 66–67

    PubMed  Google Scholar 

  24. Elonen E, Almquist A, Hännlein A et al. (1993) Intensive chemotherapy of adult AML: A randomized trial between 4 and 8 cycles. Blood 82, Suppl 1, 328a

    Google Scholar 

  25. Cassileth PA, Lynch E, Hines JD et al. (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79: 1924–1930

    PubMed  CAS  Google Scholar 

  26. Gale RP, Büchner T, Horowith MM, Zhang MJ (1993) Chemotherapy versus bone marrow transplantation for adults with acute myelogenous leukemia (AML) in first remission. Blood 82, Suppl 1: 168a

    Google Scholar 

  27. Archimbaud E, Thomas X, Michallet M et al. (1994) Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 12: 262–267

    PubMed  CAS  Google Scholar 

  28. Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL (1992) Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 10: 41–46

    PubMed  CAS  Google Scholar 

  29. Büchner T, Hiddemann W, Koenigsmann M et al. (1991) Recombinant human granulocytemacrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190–1197

    PubMed  Google Scholar 

  30. Ohno R, Tomonaga M, Kobayashi T et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323: 871–877

    Article  PubMed  CAS  Google Scholar 

  31. Rowe JM, Andersen J, Mazza JJ et al. (1993) Phase III randomized placebo-controlled study of granulocyte-macrophage-colony stimulating factor (GM-CSF) in adult patients (55–70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG). Blood 82, Suppl 1, 329a

    Google Scholar 

  32. Estey E, Thall PF, Kantarjian H et al. (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comaprison to patients treated without GM-CSF. Blood 79: 2246–2255

    PubMed  CAS  Google Scholar 

  33. Büchner T, Hiddemann W, Rottmann R et al. (1994) GM-CSF in chemotherapy for newly diagnosed AML: Multiple course priming and longterm administration compared to chemotherapy alone. In: Büchner et al. (eds): Acute Leukemias IV: 138–144

    Chapter  Google Scholar 

  34. Hiddemann W, Wörmann B, Reuter C et al. (1994) New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factor. Sem Oncol 21: 33–38

    CAS  Google Scholar 

Download references

Authors
  1. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung) Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hiddemann, W. (1995). Akute myeloische Leukämie. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10494-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10494-1_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58586-2

  • Online ISBN: 978-3-662-10494-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation